One Year Data from the Sonic Study: A Randomized, Double-Blind Trial Comparing Infliximab and Infliximab Plus Azathioprine to Azathioprine in Patients with Crohn's Disease Naive to Immunomodulators and Biologic Therapy

被引：0
|
作者：
Sandborn, William J.
Rutgeerts, Paul J.
Reinisch, Walter
Mantzaris, Gerassimos J.
Kornbluth, Asher
Rachmilewitz, Daniel
Lichtiger, Simon
D'Haens, Geert R.
van der woude, Christien J.
Diamond, Robert
Broussard, Delma
Tang, Kezhen L.
Colombel, Jean-Frederic
机构：
来源：
GASTROENTEROLOGY | 2009年 / 136卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：A116 / A116
页数：1
相关论文
共 50 条
  • [31] Double-Blind, Placebo-Controlled, 28-Week Trial of Efficacy and Safety of Infliximab Plus Naproxen Vs Naproxen Alone: Results From the Infliximab As First Line Therapy in Patients with Early, Active Axial Spondyloarthritis Trial, Part I
    Sieper, Joachim
    Lenaerts, Jan
    Wollenhaupt, Juergen
    Mazurov, Vadim
    Myasoutova, L.
    Park, Sung-Hwan
    Song, Yeong W.
    Yao, Ruji
    Chitkara, Denesh
    Vastesaeger, Nathan
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S588 - S589
  • [32] Effect of Oligofructose Enriched lnulin (OF-IN) on Bacterial Composition and Disease Activity of Crohn's Disease Patients: Results From a Double-Blind Randomized Controlled Trial
    Joossens, Marie
    De Preter, Vicky
    Ballet, Vera
    Verbeke, Kristin
    Machiels, Kathleen
    Rutgeerts, Paul J.
    Vermeire, Severine
    GASTROENTEROLOGY, 2011, 140 (05) : S19 - S20
  • [33] DISCONTINUATION OF INFLIXIMAB THERAPY IN PATIENTS WITH CROHN'S DISEASE IN SUSTAINED, COMPLETE CLINICAL-BIOCHEMICAL-ENDOSCOPIC REMISSION: A DOUBLE-BLINDED, PLACEBO-CONTROLLED, RANDOMIZED CLINICAL TRIAL
    Buhl, Sine
    Steenholdt, Casper
    Brynskov, Jorn
    Christensen, Katrine R.
    Dorn-Rasmussen, Maria
    Thomsen, Ole O.
    Bendtzen, Klaus
    Klausen, Tobias W.
    Dahlerup, Jens F.
    Thorsgaard, Niels
    Jahnsen, Jorgen
    Molazahi, Akbar
    Pedersen, Natalia
    Kjeldsen, Jens
    Almer, Sven
    Dahl, Eva E.
    Vind, Ida
    Cannon, Annett G.
    Marsal, Jan
    Sipponen, Taina
    Agnholt, Jorgen Steen
    Kievit, Hendrika A.
    Aure, Synnove L.
    Martinsen, Lars
    Meisner, Svetlana
    Moeller, Jane
    Ainsworth, Mark A.
    GASTROENTEROLOGY, 2021, 160 (06) : S151 - S152
  • [34] A Randomized, Double-Blind Study Comparing PF-06438179/GP1111, a Potential Infliximab Biosimilar, and Infliximab, Both in Combination with MTX, As Treatment for Patients with Moderate to Severe Active RA Who Have Had an Inadequate Response to MTX Therapy
    Cohen, Stanley B.
    Alten, Rieke
    Kameda, Hideto
    Rehman, Muhammad I.
    Schumacher, Karl
    Schmitt, Susanne
    Hua, Steven Y.
    Sewell, K. Lea
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [35] Does addition of infliximab to triple DMARD plus prednisolone therapy increase rate of remissions in patients with early active rheumatoid arthritis?: A randomized double-blind placebo-controlled study.
    Leirisalo-Repo, Marjatta
    Möttönen, Timo
    Hannonen, Pekka
    Korpela, Markku
    Kauppi, Markku
    Kaipiainen-Seppänen, Oili
    Luosujärvi, Riitta
    Kautiainen, Hannu
    Moilanen, Eeva
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S543 - S544
  • [36] Infliximab Maintenance Beyond One Year Prevents Postoperative Crohn's Disease Recurrence: Long-Term Follow-up From the Randomized Controlled Pilot Study
    Regueiro, Miguel
    Baidoo, Leonard
    Kip, Kevin E.
    Swoger, Jason M.
    Binion, David G.
    Hashash, Jana G.
    Schraut, Wolfgang H.
    GASTROENTEROLOGY, 2013, 144 (05) : S173 - S173
  • [37] ASPIRE (Azathioprine Secondary Progressive Interferon treated patients Randomised Evaluation) Study: preliminary safety and tolerability data from a 2-year double-blind, randomised, multicentre, pilot study
    Montanari, E
    Manneschi, L
    Pesci, I
    Merelli, E
    Motti, L
    Tola, R
    Caputo, D
    Ghezzi, A
    Scarpini, E
    Meola, G
    Durelli, L
    MULTIPLE SCLEROSIS, 2004, 10 (7032): : S261 - S261
  • [38] Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial
    Sands, Bruce E.
    Irving, Peter M.
    Hoops, Timothy
    Izanec, James L.
    Gao, Long-Long
    Gasink, Christopher
    Greenspan, Andrew
    Allez, Matthieu
    Danese, Silvio
    Hanauer, Stephen B.
    Jairath, Vipul
    Kuehbacher, Tanja
    Lewis, James D.
    Loftus, Edward V., Jr.
    Mihaly, Emese
    Panaccione, Remo
    Scherl, Ellen
    Shchukina, Oksana B.
    Sandborn, William J.
    LANCET, 2022, 399 (10342): : 2200 - 2211
  • [39] Azathioprine vs. mesalamine for prevention of post-operative clinical relapse in Crohn's disease patients with severe endoscopic recurrence: data on efficacy and safety from an IG-IBD multi-centre randomised double-blind double-dummy trial
    Orlando, A.
    Mocciaro, F.
    Ventimiglia, M.
    Renna, S.
    Scimeca, D.
    Rispo, A.
    Scribano, M. L.
    Testa, A.
    Aratari, A.
    Bossa, F.
    Angelucci, E.
    Onali, S.
    Cappello, M.
    Giunta, M.
    Castiglione, F.
    Papi, C.
    Annese, V.
    Biancone, L.
    Kohn, A.
    Di Mitri, R.
    Cottone, M.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S381 - S381
  • [40] Vedolizumab Induction Therapy for Patients With Crohn's Disease and Prior Anti-TNF Antagonist Failure: A Randomized, Placebo-controlled, Double-blind, Multicenter Trial
    Sands, Bruce
    Feagan, Brian
    Rutgeerts, Paul
    Colombel, Jean-Frederic
    Sandborn, William
    Sy, Richmond
    D'Haens, Geert
    Ben-Horin, Shomron
    Xu, Jing
    Fox, Irving
    Parikh, Asit
    Milch, Catherine
    Hanauer, Stephen
    INFLAMMATORY BOWEL DISEASES, 2012, 18 : S24 - S25
12345